SOLICITATION NOTICE
Q -- Customized rAb expression, Plasmids Preparation, Expression and Purification and QC tests
- Notice Date
- 8/18/2022 3:26:43 PM
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2132214
- Response Due
- 8/25/2022 1:00:00 PM
- Point of Contact
- DIANA ROHLMAN, Phone: 4063639366, Laura Grey, Phone: 4063759812
- E-Mail Address
-
diana.rohlman@nih.gov, laura.grey@nih.gov
(diana.rohlman@nih.gov, laura.grey@nih.gov)
- Description
- This is a Notice of Intent, not a request for proposal. �The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate with other than full and open competition basis with Genscript USA Incorporated, 860 Centennial Ave, Piscataway, NJ 08854. The NIH, NIAID, Vaccine Research Center has a need for:�Customized rAb expression, Plasmids Preparation, Expression and Purification and QC tests. The requested services for these antibody production and expression service are needed for use in critical malaria NHP trials and any alteration to this request would require re-optimization of our experimental conditions currently underway. � � Only Genscript can provide these services because they have produced these same antibodies for us before. Genscript has the expertise and knowledge needed to synthesis these complicated constructs. This service will support follow-on research needs. Also, these antibodies are currently being used in critical malaria NHP trials and any alteration to this request would require re-optimization of our experimental conditions. We have several critical experiments underway and changing the manufacturer in the middle NHP trials and experiments would increase our risk of adverse results. These antibodies were chosen based upon the intended experimental design, compatibility with current lab protocols, and the proven ability of the product to produce consistent and reliable data. �Use of another product could negatively impact the manner in which samples are processed and analyzed. Additionally, use of a different antibody would require testing by lab personnel and introduces added variability between trials. Given these urgent needs and other reasons discussed above, a change in vendor may lead to significant delays to experiments supporting these public health efforts. No substitutions are acceptable for this project to protect the integrity of the research results being conducted for these critical malaria NHP trials. �� The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. � All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2132214) to Diana Rohlman at diana.rohlman@nih.gov, by 4pm eastern standard time, August 25, 2022. �All responses received by the closing date of this synopsis will be considered by the Government. �A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. �
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/3c4f6115b2a54d759f2984ac7a5ef005/view)
- Place of Performance
- Address: Bethesda, MD 20814, USA
- Zip Code: 20814
- Country: USA
- Record
- SN06432325-F 20220820/220818230122 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |